Liraglutide side effects and risks

Reported side effects

• Nausea: Saxenda 3 mg: 39.3% versus placebo 13.8%., moderate. Small meals and fluids may help; review persistent symptoms before increasing the dose. (source)
• Diarrhea: Saxenda 3 mg: 20.9% versus placebo 9.9%., moderate. Small meals and fluids may help; review persistent symptoms before increasing the dose. (source)
• Constipation: Saxenda 3 mg: 19.4% versus placebo 8.5%., moderate. Small meals and fluids may help; review persistent symptoms before increasing the dose. (source)
• Vomiting: Saxenda 3 mg: 15.7% versus placebo 3.9%., moderate. Small meals and fluids may help; review persistent symptoms before increasing the dose. (source)
• Injection-site reactions: Saxenda: 13.9% versus placebo 10.5%., moderate. Small meals and fluids may help; review persistent symptoms before increasing the dose. (source)
• Gallstones: Saxenda: 2.2% versus placebo 0.8%; gallbladder inflammation 0.8% versus 0.4%., serious (source)
• Pancreatitis: LEADER: 0.4% versus 0.5%; rare severe and fatal cases are reported across GLP 1 medicines., serious. Stop and seek urgent assessment for persistent severe abdominal pain. (source)
• Faster resting heart rate: Saxenda mean rise 2–3 beats/minute versus placebo., moderate. Monitor resting heart rate; review a sustained increase or racing heart at rest. (source)
• Low blood sugar: Saxenda diabetes trial reports: 12.6% versus placebo 6.6%; risk depends strongly on insulin or sulfonylurea use., serious (source)
• Kidney injury from dehydration: Reported after vomiting or diarrhea; postmarketing reports do not establish a frequency., serious (source)
• Severe allergic reaction: Anaphylaxis and swelling have been reported; no reliable rate., serious (source)
• Thyroid C-cell tumors: Rodent finding; human causal risk is unknown., serious (source)

Stop and get help if

• Severe, persistent belly pain, especially spreading to the back: Stop the drug and seek urgent care for possible pancreatitis.
• Face or throat swelling, trouble breathing, or collapse: Call emergency services now; do not take another dose.
• Confusion, seizure, fainting or low blood sugar that does not resolve: Get emergency care. If awake and able to swallow, use fast sugar while help is arranged.
• Repeated vomiting, inability to keep fluids down, or very little urine: Seek urgent assessment for dehydration and kidney injury.
• Upper-right belly pain with fever, yellow skin or pale stools: Seek urgent care for possible gallbladder or bile-duct disease.
• Sudden vision loss or a major new change in vision: Get urgent same-day eye or emergency assessment.
• Chest pain, marked breathlessness or fainting: Call emergency services now.

Who should avoid it

• pregnant: Weight loss is unsuitable; fetal-risk data are limited and animal findings raise concern.
• tryingToConceive: Review a stopping plan before conception; no safe conception interval was established in the extracted sources.
• breastfeeding: Human milk and infant-safety data are inadequate.
• under18: Some labeled diabetes or obesity uses include children; this is not a blanket pediatric label ban.
• mtcOrMen2: Personal or family medullary thyroid cancer or MEN2 is a label contraindication for this GLP-1 product.
• other: Do not re-expose after a serious allergic reaction to the drug or its ingredients.
• pancreatitisHistory: Past pancreatitis needs review; stop and urgently assess persistent severe abdominal pain.
• gallbladderDisease: Gallstones or previous gallbladder inflammation increase the need to assess new upper-abdominal pain.
• gastroparesis: Severe gastroparesis is a label reason to avoid use; these medicines further slow stomach emptying.
• eatingDisorderHistory: Listed as a reason to avoid it.
• kidneyDisease: Kidney function and hydration need review, especially with vomiting or diarrhea.
• liverDisease: Clinical experience in severe liver impairment is limited; review the specific product and other medicines.
• diabeticRetinopathy: Rapid glucose improvement can temporarily worsen diabetic eye disease; arrange appropriate eye follow-up.
• surgeryPlanned: Tell the anesthesia team. Delayed stomach emptying can leave food in the stomach despite fasting.
• diabetes: Review glucose monitoring and insulin or sulfonylurea doses. Do not rapidly stop insulin.
• heartCondition: Heart rate can rise. Reduced-ejection-fraction heart-failure trials found no benefit and raised safety concerns.
• other: Xultophy contains insulin degludec and is contraindicated during an episode of low blood sugar (hypoglycemia).
• testedAthlete: Xultophy includes insulin, prohibited at all times under S4.4.2. Athletes subject to anti-doping rules need a therapeutic use exemption.
• other: Xultophy can cause life-threatening low potassium. Review potassium-lowering medicines and medicines sensitive to potassium levels; monitor when indicated.

Interactions

• Insulin: Low blood sugar risk can rise. Insulin adjustment needs glucose readings; rapid withdrawal can cause ketoacidosis.
• Sulfonylureas and related insulin-releasing drugs: Low blood sugar can increase; a clinician may need to lower the companion drug dose.
• Another GLP-1 or GLP-1/GIP medicine: Avoid duplicate incretin therapy. Switching guidance stops the previous product rather than stacking both.
• DPP-4 inhibitors: Routine combination is not recommended because it adds little glucose benefit over GLP-1 therapy alone.
• Time-sensitive oral medicines: Slower stomach emptying can alter absorption timing; the effect is medicine-specific. Review critical oral drugs, especially with vomiting or poor intake.
• Warfarin and other coumarins: The EU label recommends more frequent INR checks when starting liraglutide with warfarin or another coumarin; no direct interaction study was done.
• Thiazolidinediones with Xultophy: With Xultophy, fluid retention may cause new or worsening heart failure. Monitor for symptoms; if heart failure develops, consider lowering or stopping the TZD.

Product quality risks

• Online GLP-1 products can contain the wrong amount, a different drug or contamination. A seller’s purity claim does not establish sterile injectable quality.
• Three online semaglutide vials had 28.56–38.69% excess drug and endotoxin. Those samples were not this compound.
• MHRA found falsified Saxenda pens; some falsified GLP-1 pens contained insulin and caused severe low blood sugar.